投影分辨OCT血管成像定量评估抗VEGF治疗下1型和2型脉络膜新生血管组分
回顾性研究纳入17只未治疗渗出性年龄相关性黄斑变性眼,按PRN方案接受抗VEGF注射1年,用投影分辨OCT血管成像和卷积神经网络定量二维面积与三维体积。纯1型眼总MNV面积和体积从基线至6个月或12个月无变化(P>0.05);2型眼总MNV面积从基线至6个月和12个月显著下降(P=0.0074和P=0.014),2型组分面积从6个月0.37 mm2降至12个月0(P=0.0087)。结论认为1型和2型MNV在PRN抗VEGF治疗1年下可能有不同反应。
要点
- 纯1型MNV眼总面积和体积从基线至6或12个月无显著变化(P>0.05)。
- 2型MNV眼总面积从基线至6和12个月显著下降(P=0.0074和P=0.014)。
- 2型眼2型组分面积从6个月0.37 mm2降至12个月0(P=0.0087)。
核心结论
- 1型和2型MNV在PRN抗VEGF治疗1年下可能有不同反应。
研究设计与样本
- 回顾性研究纳入17只未治疗渗出性AMD眼,按PRN方案接受抗VEGF注射并随访1年。
- 从黄斑PR-OCTA扫描用自动卷积神经网络导出二维MNV面积和三维MNV体积,在外层视网膜层内检测血流信号,分别分析1型和2型组分。
- 17只眼中12只为纯1型MNV,5只为2型MNV。
主要发现
- 纯1型眼总MNV面积和体积从基线至6个月或12个月无变化(P>0.05)。
- 2型MNV眼总MNV面积从基线至6个月显著下降(P=0.0074),至12个月显著下降(P=0.014)。
- 2型MNV眼总MNV体积从基线至6个月和12个月下降,接近统计学显著性(P=0.061和P=0.074)。
- 2型MNV眼1型组分从0.093 mm2增至0.30 mm2(P=0.058),2型组分从6个月0.37 mm2降至12个月0(P=0.0087)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the response of type 1 and type 2 macular neovascularization (MNV) components under anti-vascular endothelial growth factor (VEGF) treatment in age-related macular degeneration (AMD) using projection-resolved optical coherence tomography angiography (PR-OCTA). METHODS: This retrospective study included eyes with treatment-naïve exudative AMD treated with anti-VEGF injections under a pro re nata (PRN) protocol over 1 year. Two-dimensional MNV areas and three-dimensional MNV volumes were derived from macular PR-OCTA scans using an automated convolutional neural network. MNV was detected as flow signal within the outer retinal slab. Type 1 components and type 2 components were analyzed separately. RESULTS: Of 17 enrolled eyes, 12 eyes were pure type 1 MNV and five eyes were type 2 MNV. In eyes with pure type 1, the total (sum of type 1 and type 2 components) MNV area and volume did not change from baseline to 6 months or 12 months (P > 0.05). In eyes with type 2 MNV, the total MNV area significantly decreased from the baseline to 6 months (P = 0.0074) and 12 months (P = 0.014). The total type 2 MNV volume also decreased from baseline visit to visits at 6 months and at 12 months, nearing statistical signifiicance (P = 0.061 and P = 0.074). In eyes with type 2 MNV, the type 1 component increased from 0.093 mm2 to 0.30 mm2 (P = 0.058), and the type 2 component decreased from 0.37 mm2 at 6 months to 0 at 12 months (P = 0.0087). CONCLUSIONS: Type 1 and type 2 MNV may have different response under PRN anti-VEGF treatment over 1 year.
引用
- Tsuboi K, You QS, Wang J, et al. Quantitative Evaluation of Type 1 and Type 2 Choroidal Neovascularization Components Under Treatment With Projection-Resolved OCT Angiography. Invest Ophthalmol Vis Sci. 2024. PMID: 39302645. doi:10.1167/iovs.65.11.32
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。